TP53 and ovarian carcinoma: Disruption of mortalin/p53 complexes by SHetA2 was shown to prevent establishment of ovarian cancer without toxicity in a preclinical model of ovarian cancer maintenance therapy [78], thus suggesting a role for mortalin inhibitors in secondary cancer prevention.